{"id":161730,"date":"2021-01-22T16:24:33","date_gmt":"2021-01-22T13:24:33","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/one-shot-covid-vaccine-could-give-johnson-johnson-an-edge\/"},"modified":"2021-01-22T16:24:33","modified_gmt":"2021-01-22T13:24:33","slug":"one-shot-covid-vaccine-could-give-johnson-johnson-an-edge","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/one-shot-covid-vaccine-could-give-johnson-johnson-an-edge\/","title":{"rendered":"#One-shot COVID vaccine could give Johnson & Johnson an edge"},"content":{"rendered":"

“#One-shot COVID vaccine could give Johnson & Johnson an edge<\/strong>”<\/p>\n

\n

Less may be more when it comes to rolling out a coronavirus vaccine.<\/p>\n

Johnson & Johnson\u2019s one-dose vaccine could have an edge over Pfizer and Moderna\u2019s shots \u2014 even though it\u2019s still several weeks away from app<\/a>roval in the US, Wall Street analysts told The Post.<\/p>\n

That\u2019s because the single jab will likely be easier to distribute across the country than its rivals\u2019 two-dose regimens that are slowly going into Americans\u2019 arms.<\/p>\n

\u201cThey are not that late, considering the fact that they are shooting for a one-dose vaccine, which is definitely going be way more convenient,\u201d CFRA Research analyst Sel Hardy told The Post. \u201cThey have clear advantages in terms of logistics.\u201d<\/p>\n

J&J expects to release data from its large-scale vaccine study in late January and ask the feds to clear the shot for emergency use soon thereafter. That would put it roughly two months behind Pfizer and Moderna, which won emergency approvals in mid-December.<\/p>\n

J&J \u2014 which reportedly hopes to have\u00a0enough vaccines for 100 million Americans by April \u2014\u00a0is also studying a two-dose regimen, but just one dose generated an immune response in more than 90 percent of the participants in an early clinical trial.<\/p>\n

\"A
Johnson & Johnson\u2019s one-dose COVID-19 vaccine is still several weeks away from approval in the US.<\/figcaption>
REUTERS\/Ivan Alvarado<\/span><\/figcaption><\/figure>\n

That means each dose the New Jersey-based company produces could inoculate one person, potentially doubling its impact compared to the Pfizer and Moderna jabs, according to Jeylan Mammadova of Third Bridge.<\/p>\n

\u201cIf I am saying that I have the capacity to produce a billion doses \u2026 that\u2019s a billion people that you\u2019re vaccinating\u201d with a one-shot vaccine, said Mammadova, the investment research firm\u2019s global team lead for health care. \u201cIf I make the same statement with Moderna and with Pfizer, that\u2019s only half.\u201d<\/p>\n

There\u2019s another key difference \u2014 J&J\u2019s shot provokes an immune response in the body by delivering a gene for the coronavirus \u201cspike\u201d proteins through a common-cold virus that can\u2019t make the recipient sick. That\u2019s a different method from the so-called messenger RNA found in the Moderna and Pfizer vaccines.<\/p>\n

The J&J technology<\/a> already has a strong track record \u2014 it was used to develop the company\u2019s Ebola vaccine<\/a> that European Union regulators approved last July. That could help reassure people who are skeptical of the brand-new COVID-19 shots, according to analysts.<\/p>\n

\u201cAlthough they are late, some people might think, \u2018OK, they are using a traditional vaccine platform,\u2019\u201d Hardy said. \u201cThere could also be a confidence issue, a perception issue, I would say, that could play to their advantage.\u201d<\/p>\n

What\u2019s more, J&J\u2019s vaccine is expected to have a longer shelf life<\/a> than Moderna\u2019s and doesn\u2019t require ultra-cold storage like Pfizer\u2019s, which has to be kept at minus 94 degrees Fahrenheit to be effective.<\/p>\n

J&J estimates its vaccine will stay stable for at least three months at standard refrigerator temperatures and for two years in a freezer at minus 4 degrees Fahrenheit. Moderna\u2019s<\/a>, on the other hand, can last up to just 30 days in the fridge and up to six months when frozen.<\/p>\n

Despite these apparent advantages, analysts don\u2019t expect the vaccine to have a big impact on J&J\u2019s bottom line. The firm has said it plans to make the shot available on a \u201cnot-for-profit basis for emergency pandemic use,\u201d and it got about $454 million<\/a> in research and development funding from the US government.<\/p>\n

J&J will also eventually have to go head to head with other single-dose COVID vaccines from companies such as Merck<\/a>, which is further behind in development<\/a>.<\/p>\n

\u201cI don\u2019t think financially it makes any difference to [J&J] even if it\u2019s a fantastic win,\u201d Sam Fazeli, senior pharmaceuticals analyst for Bloomberg Intelligence, told The Post. \u201cThe question is whether this is something they\u2019re going to be able to monetize beyond the pandemic.\u201d\n <\/p><\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

For forums sites go to Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

\n

If you want to read more News<\/a> articles, you can visit our News category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

“#One-shot COVID vaccine could give Johnson & Johnson an edge” Less may be more when it comes to rolling out a coronavirus vaccine. Johnson & Johnson\u2019s one-dose vaccine could have an edge over Pfizer and Moderna\u2019s shots \u2014 even though it\u2019s still several weeks away from approval in the US, Wall Street analysts told The…<\/p>\n","protected":false},"author":1,"featured_media":161731,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/nypost.com\/wp-content\/uploads\/sites\/2\/2021\/01\/johnson-johnson-vaccine-63.jpg?quality=90&strip=all&w=1200","fifu_image_alt":"","footnotes":""},"categories":[70897],"tags":[90358,1545,82862,71061,73840],"class_list":["post-161730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-1-22-21","tag-coronavirus","tag-covid-vaccine","tag-johnson-johnson","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/161730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=161730"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/161730\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/161731"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=161730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=161730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=161730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}